Phostin Therapeutics

📍 Montpellier, France👥 14 employees💰 Last funded 2020
Biotechnology Research🌐 phostin.com
Website LinkedIn
Phost’in Therapeutics discovers and develops First-In-Class Glycocalyx Modifiers for selective treatment of cancers and other serious diseases. A new and innovative player in the field of Glyco-Immuno-Oncology, Phost’in Therapeutics develops a class of highly potent anti-cancer NCEs (new chemical entities) targeting a key glycosylation mechanism responsible for suppressing the immune response. Our first generation of Glycosylation inhibitors aims to unblock immune response and down-modulate invasiveness for the treatment of aggressive solid tumors.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Japan
1
Frequently asked questions
Who invested in Phostin Therapeutics?
Phostin Therapeutics has 1 investors on record on gritt.io.
When did Phostin Therapeutics last raise funding?
The most recent investment in Phostin Therapeutics recorded on gritt.io was in 2020.
What industry is Phostin Therapeutics in?
Phostin Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Phostin Therapeutics based?
Phostin Therapeutics is headquartered in Montpellier, France.